Aptose Biosciences Inc. has rescheduled its special meeting of shareholders to a later date in January 2026. The Meeting was originally set for January 16, 2026. The Meeting will still include the previously announced continuance of Aptose and the subsequent acquisition by Hanmi Pharmaceutical Co. Ltd. Aptose received an interim order from the Court of King’s Bench of Alberta to authorize the Meeting. The Company’s board unanimously recommends shareholders vote FOR the special resolutions at the Meeting. Aptose is a biotechnology company focused on developing precision medicines for oncology, initially targeting hematology.

Read more at GlobeNewswire: Aptose Biosciences Announces Rescheduling of Special